🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Pharmaniaga Berhad (KLSE:PHARMA)
Malaysia flag Malaysia · Delayed Price · Currency is MYR
0.7400
-0.0200 (-2.63%)
At close: Nov 20, 2026

Pharmaniaga Berhad Statistics

Total Valuation

KLSE:PHARMA has a market cap or net worth of MYR 970.44 million. The enterprise value is 1.63 billion.

Market Cap970.44M
Enterprise Value 1.63B

Important Dates

The next estimated earnings date is Friday, November 27, 2026.

Earnings Date Nov 27, 2026
Ex-Dividend Date Dec 23, 2026

Share Statistics

KLSE:PHARMA has 1.31 billion shares outstanding. The number of shares has increased by 182.17% in one year.

Current Share Class 1.31B
Shares Outstanding 1.31B
Shares Change (YoY) +182.17%
Shares Change (QoQ) n/a
Owned by Insiders (%) 6.34%
Owned by Institutions (%) 13.96%
Float 341.00M

Valuation Ratios

The trailing PE ratio is 12.49 and the forward PE ratio is 10.72.

PE Ratio 12.49
Forward PE 10.72
PS Ratio 0.23
PB Ratio 2.03
P/TBV Ratio 2.50
P/FCF Ratio 50.49
P/OCF Ratio 8.66
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.08, with an EV/FCF ratio of 84.86.

EV / Earnings 20.93
EV / Sales 0.39
EV / EBITDA 10.08
EV / EBIT 12.75
EV / FCF 84.86

Financial Position

The company has a current ratio of 1.00, with a Debt / Equity ratio of 1.51.

Current Ratio 1.00
Quick Ratio 0.53
Debt / Equity 1.51
Debt / EBITDA 4.71
Debt / FCF 39.62
Interest Coverage 2.91

Financial Efficiency

Return on equity (ROE) is 16.98% and return on invested capital (ROIC) is 10.37%.

Return on Equity (ROE) 16.98%
Return on Assets (ROA) 3.31%
Return on Invested Capital (ROIC) 10.37%
Return on Capital Employed (ROCE) 15.02%
Weighted Average Cost of Capital (WACC) 7.11%
Revenue Per Employee 1.19M
Profits Per Employee 22,252
Employee Count3,502
Asset Turnover 1.73
Inventory Turnover 5.54

Taxes

In the past 12 months, KLSE:PHARMA has paid 7.80 million in taxes.

Income Tax 7.80M
Effective Tax Rate 8.80%

Stock Price Statistics

The stock price has decreased by -38.33% in the last 52 weeks. The beta is 0.79, so KLSE:PHARMA's price volatility has been lower than the market average.

Beta (5Y) 0.79
52-Week Price Change -38.33%
50-Day Moving Average 0.90
200-Day Moving Average 1.17
Relative Strength Index (RSI) 33.97
Average Volume (20 Days) 1,587,130

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, KLSE:PHARMA had revenue of MYR 4.17 billion and earned 77.93 million in profits. Earnings per share was 0.06.

Revenue4.17B
Gross Profit 426.36M
Operating Income 127.90M
Pretax Income 88.69M
Net Income 77.93M
EBITDA 151.25M
EBIT 127.90M
Earnings Per Share (EPS) 0.06
Full Income Statement

Balance Sheet

The company has 125.89 million in cash and 761.56 million in debt, with a net cash position of -635.67 million or -0.48 per share.

Cash & Cash Equivalents 125.89M
Total Debt 761.56M
Net Cash -635.67M
Net Cash Per Share -0.48
Equity (Book Value) 502.79M
Book Value Per Share 0.36
Working Capital 5.34M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 112.00 million and capital expenditures -92.78 million, giving a free cash flow of 19.22 million.

Operating Cash Flow 112.00M
Capital Expenditures -92.78M
Depreciation & Amortization 23.35M
Net Borrowing -163.90M
Free Cash Flow 19.22M
FCF Per Share 0.01
Full Cash Flow Statement

Margins

Gross margin is 10.22%, with operating and profit margins of 3.07% and 1.87%.

Gross Margin 10.22%
Operating Margin 3.07%
Pretax Margin 2.13%
Profit Margin 1.87%
EBITDA Margin 3.62%
EBIT Margin 3.07%
FCF Margin 0.46%

Dividends & Yields

This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 2.77%.

Dividend Per Share 0.02
Dividend Yield 2.77%
Dividend Growth (YoY) n/a
Years of Dividend Growth 2
Payout Ratio 21.04%
FCF Payout Ratio 139.86%
Buyback Yield -182.17%
Shareholder Yield -179.40%
Earnings Yield 8.01%
FCF Yield 1.98%
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Analyst Forecast

The average price target for KLSE:PHARMA is 1.45, which is 96.35% higher than the current price. The consensus rating is "Buy".

Price Target 1.45
Price Target Difference 96.35%
Analyst Consensus Buy
Analyst Count 3
Revenue Growth Forecast (3Y) 5.47%
EPS Growth Forecast (3Y) 8.26%

Stock Splits

The last stock split was on June 8, 2026. It was a reverse split with a ratio of 0.2.

Last Split Date Jun 8, 2026
Split Type Reverse
Split Ratio 0.2

Scores

KLSE:PHARMA has an Altman Z-Score of 2.49 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.49
Piotroski F-Score 6